Vodafone Group Plc (ADR) (NASDAQ:VOD) made an announcement that it is going to establish a new hub for the innovation of global products and services of the company in London. The main aim of this hub will be the improvement in development activities, which will further help the company to come closer to its customers in Europe, India and Africa. This will further enable the company to earn benefit from the wealth of talent and technology skills from UK and Europe. Vodafone Group Plc (ADR) (NASDAQ:VOD) weekly performance is -2.40%. On last trading day company shares ended up $32.88. Analysts mean target price for the company is $47.28. Vodafone Group Plc (ADR) (NASDAQ:VOD) distance from 50-day simple moving average (SMA50) is -5.32%.
Shares of Cree Inc (NASDAQ:CREE) saw some unusual options trading on Friday. Stock traders acquired 29,936 call options on the stock, Analyst Ratings News reports. This represents an increase of 486% compared to the typical daily volume of 5,109 call options. Cree, Inc. (NASDAQ:CREE) shares advanced 5.01% in last trading session and ended the day on $49.66. Gross Margin is 37.70% and its return on assets is 3.80%. Cree, Inc. (NASDAQ:CREE) quarterly performance is -17.70%.
June 10 — Fusion-IO, Inc. (NYSE:FIO) announced that HP is the first-to-market Original Equipment Manufacturer (OEM) server partner to offer Atomic Series, the newest flash memory platform featuring industry leading performance, proven reliability and the largest capacities of up to 6.4TB per product. Companies both big and small that deploy HP ProLiant Servers in their datacenters can now integrate Atomic Series to power application acceleration. Fusion-IO, Inc. (NYSE:FIO) shares moved up 5.10% in last trading session and was closed at $9.28, while trading in range of $8.94 – $9.49. Fusion-IO, Inc. (NYSE:FIO) year to date (YTD) performance is 4.15%.
TG Therapeutics, Inc. (NASDAQ:TGTX) an innovative, clinical-stage biopharmaceutical company announced preliminary clinical results from its ongoing Phase 2 study of TG-1101 (ublituximab), the Company’s novel glycoengineered anti-CD20 monoclonal antibody, in combination with ibrutinib (IMBRUVICA(TM)), the oral BTK inhibitor from Pharmacyclics/Janssen. Data from the Phase 2 study is being presented during the 19th Annual European Hematology Association (EHA) meeting being held in Milan, Italy. TG Therapeutics, Inc. (NASDAQ:TGTX) ended the last trading day at $9.61. Company weekly volatility is calculated as 16.80% and price to cash ratio as 6.76. TG Therapeutics, Inc. (NASDAQ:TGTX) showed a positive weekly performance of 47.85%.
June 2, 2014 — OTC Markets Group Inc. (otcqx:OTCM), operator of Open, Transparent and Connected financial marketplaces, announced that LONESTAR RESOURCES (OTCMKTS:LNREF) an oil and gas exploration company based in Fort Worth, Texas, has been approved to trade on OTCQX®, the best marketplace with qualified companies. LONESTAR RESOURCES (OTCMKTS:LNREF) On last trading day company shares ended up $0.408 .
Leave a Reply